Clinical Study to Evaluate the Safety and Tolerability of PRO-229 Ophthalmic Solution Compared to Lagricel® Ofteno PF

NCT06370585 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

Dry Eye Disease
Ocular Surface Disease

Interventions

DRUG: PRO-229
DRUG: Lagricel® Ofteno PF

Sponsor

Laboratorios Sophia S.A de C.V.